TIGIT and neoplasm: Some studies have shown that co-expression of TIGIT and PD-1 could lead to impaired protective anti-tumor responses; therefore, antibody co-blockade of TIGIT and PD-1 could enhance CD8+ T-cell effector function, resulting in significant tumor clearance (40, 41).